List of agents with preclinical evidence of synergy in combination with venetoclax in AML models
| Drug name . | Drug class . |
|---|---|
| Chemotherapy | |
| Daunorubicin35 | Anthracycline |
| Cytarabine35 | Nucleoside analog |
| Epigenetic regulators | |
| Azacitidine36-38 | Hypomethylating agent |
| Panobinostat39 | Histone deacetylase inhibitor |
| Targeted agents | |
| Alvocidib (flavopiridol)40 | CDK9 inhibitor |
| MLN4924 (pevonedistat)41 | NED inhibitor |
| GDC-098042 | PI3K/mTOR inhibitor |
| RG7388 (idasanutlin)43,44 | MDM2 antagonist |
| GDC-0973 (cobimetinib)45 | MEK inhibitor |
| A-121047746 | MCL-1 inhibitor |
| VU66101347 | MCL-1 inhibitor |
| AMG 17648 | MCL-1 inhibitor |
| Quizartinib49 | FLT3 inhibitor |
| Enasidenib50,51 | IDH2 inhibitor |
| Drug name . | Drug class . |
|---|---|
| Chemotherapy | |
| Daunorubicin35 | Anthracycline |
| Cytarabine35 | Nucleoside analog |
| Epigenetic regulators | |
| Azacitidine36-38 | Hypomethylating agent |
| Panobinostat39 | Histone deacetylase inhibitor |
| Targeted agents | |
| Alvocidib (flavopiridol)40 | CDK9 inhibitor |
| MLN4924 (pevonedistat)41 | NED inhibitor |
| GDC-098042 | PI3K/mTOR inhibitor |
| RG7388 (idasanutlin)43,44 | MDM2 antagonist |
| GDC-0973 (cobimetinib)45 | MEK inhibitor |
| A-121047746 | MCL-1 inhibitor |
| VU66101347 | MCL-1 inhibitor |
| AMG 17648 | MCL-1 inhibitor |
| Quizartinib49 | FLT3 inhibitor |
| Enasidenib50,51 | IDH2 inhibitor |